Radioimmunotherapy using antibodies shows promise for Prostate Cancer patients offering treatment options that include less Lutetium dose, less number or treatments, less concern about saliva gland toxicity and importantly, highly targeted tumors. Hear more from Nat Lenzo, MD, Group Clinical Director of Theranostics and Molecular Imaging, GenesisCare, as he explains the method of action (MOA) and biodistribution advantages of PSMA Radioligand Therapy.
Supported by Telix Pharmaceuticals as a service to medicine - Telix respects the independence of healthcare professionals and the views are those of the presenter.
Back To TopPSMA Radioligand Therapy | Advances in Prostate Cancer Treatments | Part 1. Appl Rad Oncol.
